Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A

5(71.4%)

Phase 1

2(28.6%)

7Total

N/A(5)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07298200Phase 1Recruiting

Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer

Role: collaborator

NCT06353646Not ApplicableRecruiting

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Role: collaborator

NCT07329894Phase 1Recruiting

Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer

Role: collaborator

NCT05940181Not ApplicableUnknown

A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid Tumors

Role: collaborator

NCT05359354Not ApplicableUnknown

Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors

Role: collaborator

NCT05192460Not ApplicableUnknown

Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver Cancer

Role: collaborator

NCT05227378Not ApplicableUnknown

Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer

Role: collaborator

All 7 trials loaded